7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 
      
    		                                
      assets
    		                                
      current assets:
    		                                
      cash and cash equivalents
    		90,963,000 141,207,000 56,947,000 174,960,000 90,636,000 74,679,000 60,574,000 127,106,000 148,011,000 131,973,000 68,131,000 218,044,000 118,615,000 155,088,000 104,953,000 293,477,000 394,553,000 485,680,000 435,321,000 507,144,000 351,047,000 137,184,000 207,537,000 79,449,000 82,673,000 62,936,000 39,661,000 77,123,000 43,651,000 33,088,000 44,001,000  
      short-term marketable securities
    		757,241,000 757,745,000 760,979,000 657,371,000 745,923,000 821,365,000 876,295,000 907,405,000 961,245,000 1,059,014,000 1,220,322,000 1,118,171,000 987,440,000 913,580,000 852,569,000 571,930,000 644,622,000 823,251,000 977,827,000 962,553,000 610,154,000 412,397,000 379,713,000 335,907,000 396,717,000 415,667,000 445,820,000 387,174,000 331,307,000 339,503,000 329,401,000  
      prepaid expenses and other current assets
    		34,394,000 35,754,000 60,712,000 32,105,000 32,280,000 32,339,000 36,706,000 29,626,000 33,628,000 33,075,000 36,709,000 36,104,000 32,471,000 45,575,000 30,914,000 30,601,000 15,140,000 16,029,000 15,963,000 20,284,000 9,665,000 9,828,000 17,535,000 14,675,000 14,987,000 17,378,000 14,052,000 16,539,000 8,445,000 4,827,000 4,020,000  
      total current assets
    		882,598,000 934,706,000 878,638,000 864,436,000 868,839,000 928,383,000 973,575,000 1,064,137,000 1,142,884,000 1,224,062,000 1,325,162,000 1,372,319,000 1,138,526,000 1,114,600,000 988,436,000 897,234,000 1,055,509,000 1,341,745,000 1,431,622,000 1,495,655,000 970,866,000 559,409,000 604,785,000 430,031,000 494,377,000 495,981,000 499,533,000 480,836,000 383,403,000 377,418,000 377,422,000  
      long-term marketable securities
    		24,703,000 78,463,000 235,844,000 359,373,000 445,463,000 450,994,000 490,723,000  7,905,000     94,220,000 250,268,000 425,449,000 319,472,000 92,522,000 38,885,000 32,699,000 20,341,000 7,229,000 9,684,000 39,886,000 23,534,000 55,832,000 97,554,000 147,881,000 142,173,000 178,703,000 219,406,000  
      property and equipment
    		53,732,000 58,717,000 57,765,000 55,236,000 50,822,000 48,077,000 46,863,000 45,589,000 48,101,000 39,821,000 42,117,000 44,087,000 41,692,000 38,703,000 37,679,000 38,865,000 40,012,000 40,350,000 41,376,000 40,846,000 42,265,000 43,622,000 45,452,000 46,732,000 47,481,000 47,195,000 36,955,000 25,162,000 16,245,000 13,323,000 14,860,000  
      finance lease right-of-use asset
    		49,447,000 50,363,000 50,199,000 47,533,000 38,685,000                            
      operating lease right-of-use asset
    		20,035,000 21,022,000 21,963,000 22,861,000 23,717,000 24,533,000 25,309,000 26,048,000      29,755,000 30,263,000 30,743,000 31,196,000 31,622,000 32,236,000 32,618,000 32,976,000 33,312,000 33,626,000 33,923,000 34,344,000 34,647,000 34,407,000      
      other non-current assets
    		25,106,000 22,970,000 26,934,000 24,741,000 26,487,000 50,578,000 44,621,000 18,143,000 11,137,000 14,434,000 14,016,000 13,399,000 16,117,000 15,184,000 14,212,000 11,871,000 3,777,000 3,576,000 3,739,000 2,462,000 3,858,000 3,765,000 2,318,000 2,659,000 3,242,000 3,949,000 8,147,000 8,105,000 2,654,000 2,611,000 2,265,000  
      total assets
    		1,055,621,000 1,166,241,000 1,271,343,000 1,374,180,000 1,454,013,000 1,502,565,000 1,581,091,000 1,153,917,000 1,236,777,000 1,305,734,000 1,409,344,000 1,460,242,000 1,227,606,000 1,292,462,000 1,320,858,000 1,404,162,000 1,449,966,000 1,509,815,000 1,547,858,000 1,604,280,000 1,070,306,000 647,337,000 695,865,000 553,231,000 602,978,000 637,604,000 676,596,000 661,984,000 544,475,000 572,055,000 613,953,000 486,721,000 
      liabilities and stockholders' equity
    		                                
      current liabilities:
    		                                
      accounts payable
    		6,745,000 10,844,000 8,458,000 11,137,000 9,594,000 13,936,000 11,855,000 9,483,000 1,182,000 8,520,000 2,215,000 2,790,000 7,539,000 7,116,000 3,358,000 4,779,000 4,817,000 4,235,000 1,626,000 1,071,000 2,806,000 1,866,000 2,316,000 2,590,000 2,022,000 3,931,000 3,662,000 1,891,000 3,354,000 9,176,000 1,377,000  
      accrued compensation
    		18,358,000 12,068,000 7,655,000  14,874,000 9,555,000 8,053,000  16,344,000 10,256,000 7,365,000  13,253,000 8,315,000 5,844,000  10,534,000 6,295,000 4,963,000  9,010,000 5,531,000 3,910,000  7,528,000 4,092,000 3,213,000 9,952,000 4,847,000 2,751,000 1,994,000  
      accrued clinical and other research and development costs
    		23,355,000 23,379,000 27,908,000  23,923,000                            
      accrued manufacturing costs
    		5,002,000 9,028,000 14,579,000  9,568,000 7,111,000 16,720,000  12,421,000 17,263,000 19,959,000  16,732,000 17,929,000 11,366,000  13,142,000 13,052,000 13,342,000              
      operating lease liability, current
    		9,164,000 8,871,000 8,585,000  8,036,000 7,771,000 7,512,000       5,871,000 5,659,000  5,252,000 5,055,000 4,876,000  4,508,000 4,330,000 4,121,000          
      deferred research and development funding liability, current
    		22,580,000 19,861,000 17,338,000  16,269,000                            
      other accrued costs and current liabilities
    		4,942,000 7,006,000 7,354,000  4,829,000 6,013,000 5,986,000  9,331,000 3,603,000 9,136,000  2,395,000 2,076,000 2,390,000  2,364,000 2,148,000               
      total current liabilities
    		90,146,000 91,057,000 91,877,000 102,208,000 87,093,000 74,533,000 82,582,000 77,982,000 71,180,000 69,357,000 391,080,000 363,922,000 360,670,000 348,160,000 341,240,000 378,245,000 54,251,000 51,412,000 54,610,000 71,699,000 105,413,000 58,464,000 47,635,000 45,344,000 46,685,000 46,549,000 43,244,000 32,786,000 31,617,000 31,008,000 17,167,000  
      operating lease liability, less current portion
    		29,686,000 32,110,000 34,449,000 36,673,000 38,850,000 40,981,000 43,034,000 44,981,000      55,525,000 57,086,000 58,554,000 59,990,000 61,396,000 62,916,000 64,175,000 65,407,000 66,612,000 67,793,000 68,865,000 69,915,000 70,911,000 71,412,000      
      finance lease liability, less current portion
    		5,554,000 5,577,000 5,598,000 5,615,000 5,631,000                            
      deferred research funding and development liability, less current portion
    		4,038,000 10,444,000 16,733,000  3,944,000                            
      total liabilities
    		129,424,000 139,188,000 148,657,000 144,496,000 135,518,000 115,514,000 125,616,000 122,963,000 118,446,000 118,909,000 442,638,000 417,812,000 416,303,000 408,014,000 402,931,000 441,871,000 437,689,000 437,110,000 442,505,000 453,749,000 187,756,000 145,170,000 150,554,000 158,341,000 164,781,000 162,431,000 159,948,000 115,139,000 83,296,000 81,783,000 74,925,000 20,925,000 
      commitments and contingencies
    		                                
      stockholders' equity:
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2025 and december 31, 2024; 0 shares issued and outstanding as of september 30, 2025 and december 31, 2024
    		                                
      common stock
    		1,793,000 1,783,000 1,778,000 1,768,000 1,764,000 1,757,000 1,751,000 1,711,000 1,707,000 1,700,000 1,694,000 1,686,000 1,564,000 1,558,000 1,554,000 1,548,000 1,545,000 1,541,000 1,537,000 1,531,000 1,524,000 1,385,000 1,382,000 1,288,000 1,286,000 1,283,000 1,279,000 1,273,000 1,266,000 1,259,000 1,252,000  
      additional paid-in capital
    		2,846,278,000 2,820,404,000 2,790,825,000 2,764,880,000 2,735,433,000 2,704,992,000 2,673,033,000 2,144,811,000 2,114,013,000 2,083,951,000 2,048,297,000 2,018,617,000 1,693,901,000 1,664,174,000 1,635,840,000 1,608,238,000 1,580,988,000 1,556,679,000 1,528,504,000 1,503,660,000 1,480,315,000 1,041,303,000 1,025,408,000 818,803,000 807,875,000 798,277,000 781,966,000 774,158,000 766,799,000 760,605,000 754,438,000  
      accumulated other comprehensive income
    		1,101,000 939,000 2,037,000 2,020,000 5,529,000 -2,659,000 -1,296,000 643,000            -245,000 11,000 551,000 835,000 350,000 562,000 879,000 332,000      
      accumulated deficit
    		-1,922,975,000 -1,796,073,000 -1,671,954,000 -1,538,984,000 -1,424,231,000 -1,317,039,000 -1,218,013,000 -1,116,211,000 -996,738,000 -897,385,000 -1,080,768,000 -970,987,000 -872,309,000 -769,010,000 -710,216,000 -644,996,000 -569,735,000 -485,147,000 -424,456,000 -354,415,000 -599,300,000 -541,072,000 -482,314,000 -425,551,000 -371,526,000 -325,266,000 -266,929,000 -227,937,000 -305,470,000 -270,099,000 -215,375,000 -191,697,000 
      total stockholders' equity
    		926,197,000 1,027,053,000 1,122,686,000  1,318,495,000 1,387,051,000 1,455,475,000  1,118,331,000 1,186,825,000 966,706,000  811,303,000 884,448,000 917,927,000  1,012,277,000 1,072,705,000 1,105,353,000  882,550,000 502,167,000 545,311,000  438,197,000 475,173,000 516,648,000  461,179,000 490,272,000   
      total liabilities and stockholders’ equity
    		1,055,621,000 1,166,241,000 1,271,343,000 1,374,180,000 1,454,013,000 1,502,565,000 1,581,091,000 1,153,917,000 1,236,777,000 1,305,734,000 1,409,344,000 1,460,242,000 1,227,606,000 1,292,462,000 1,320,858,000 1,404,162,000 1,449,966,000 1,509,815,000 1,547,858,000 1,604,280,000 1,070,306,000 647,337,000 695,865,000 553,231,000 602,978,000 637,604,000 676,596,000 661,984,000 544,475,000 572,055,000 613,953,000  
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2025 and december 31, 2024; 0 shares issued and outstanding as of june 30, 2025 and december 31, 2024
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2025 and december 31, 2024; 0 shares issued and outstanding as of march 31, 2025 and december 31, 2024
    		                                
      liabilities and stockholders’ equity
    		                                
      accrued expenses and other current liabilities
    		   91,071,000    68,499,000    66,691,000    53,165,000    47,145,000    24,015,000         
      stockholders’ equity:
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2024 and december 31, 2023; 0 shares issued and outstanding as of december 31, 2024 and december 31, 2023
    		                                
      total stockholders’ equity
    		   1,229,684,000    1,030,954,000    1,042,430,000    962,291,000    1,150,531,000    394,890,000    546,845,000   539,028,000 465,796,000 
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2024 and december 31, 2023; 0 shares issued and outstanding as of september 30, 2024 and december 31, 2023
    		                                
      accrued clinical and other research & development costs
    		     19,915,000 19,956,000  14,534,000 15,120,000 47,571,000  21,701,000 16,429,000 19,283,000  13,380,000 11,434,000               
      deferred research funding liability
    		     10,232,000                           
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2024 and december 31, 2023; 0 shares issued and outstanding as of june 30, 2024 and december 31, 2023
    		                                
      deferred research funding liability, current
    		      12,500,000                          
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2024 and december 31, 2023; 0 shares issued and outstanding as of march 31, 2024 and december 31, 2023
    		                                
      cost sharing payments due to related party
    		        10,354,000 6,976,000 8,538,000 4,388,000 1,443,000  2,713,000                  
      related party contract liability, current
    		           290,053,000   290,627,000 292,386,000 3,438,000 3,438,000 3,569,000 3,569,000             
      related party contract liability, less current portion
    		           479,000   828,000 1,295,000 291,434,000 292,293,000 292,956,000 293,849,000             
      other non-current liabilities
    		        379,000 379,000 379,000 379,000 379,000 379,000 379,000 379,000 701,000 701,000 701,000 701,000 379,000 379,000 379,000 379,000 386,000 408,000 440,000 471,000 124,000 156,000 188,000  
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2023 and december 31, 2022; 0 shares issued and outstanding as of december 31, 2023 and december 31, 2022
    		                                
      operating lease right-of-use assets
    		        26,750,000 27,417,000 28,049,000 30,437,000 31,271,000                    
      operating lease liabilities, current
    		        7,014,000 6,774,000 6,539,000  7,068,000                    
      related-party contract liability, current
    		         845,000 289,757,000  290,516,000 290,424,000                   
      related-party contract liability, less current portion
    		         422,000 633,000  276,000 552,000                   
      operating lease liabilities, less current portion
    		        46,887,000 48,751,000 50,546,000 53,032,000 54,978,000                    
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2023 and december 31, 2022; 0 shares issued and outstanding as of september 30, 2023 and december 31, 2022
    		                                
      accumulated other comprehensive loss
    		        -651,000 -1,441,000 -2,517,000 -6,886,000 -11,853,000 -12,274,000 -9,251,000 -2,499,000 -521,000 -368,000 -232,000         -649,000 -1,416,000 -1,493,000 -1,287,000  
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2023 and december 31, 2022; 0 shares issued and outstanding as of june 30, 2023 and december 31, 2022
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2023 and december 31, 2022; 0 shares issued and outstanding as of march 31, 2023 and december 31, 2022
    		                                
      cost sharing reimbursements due from related party
    		             357,000  1,226,000 1,194,000 1,567,000 2,511,000 5,674,000             
      contract liabilities, current
    		            23,000   27,915,000 1,324,000 5,755,000 12,886,000 19,914,000             
      contract liabilities, less current portion
    		             3,398,000 3,398,000 3,398,000 31,313,000 31,308,000 31,322,000 23,325,000 16,557,000 19,715,000 34,747,000 43,753,000 47,795,000 44,563,000 44,852,000      
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2022 and december 31, 2021; 0 shares issued and outstanding as of december 31, 2022 and december 31, 2021
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2022 and december 31, 2021; 0 shares issued and outstanding as of september 30, 2022 and december 31, 2021
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2022 and december 31, 2021; 0 shares issued and outstanding as of june 30, 2022 and december 31, 2021
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2022 and december 31, 2021; 0 shares issued and outstanding as of march 31, 2022 and december 31, 2021
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2021 and december 31, 2020; 0 shares issued and outstanding as of december 31, 2021 and december 31, 2020
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2021 and december 31, 2020; 0 shares issued and outstanding as of september 30, 2021 and december 31, 2020
    		                                
      accounts receivable
    		                 15,218,000               
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2021 and december 31, 2020; 0 shares issued and outstanding as of june 30, 2021 and december 31, 2020
    		                                
      accrued clinical costs
    		                  5,049,000  4,689,000 4,179,000 5,349,000          
      other accruals and other current liabilities
    		                  8,299,000  11,531,000 8,424,000 7,265,000          
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2021 and december 31, 2020; 0 shares issued and outstanding as of march 31, 2021 and december 31, 2020
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2020 and december 31, 2019; 0 shares issued and outstanding as of december 31, 2020 and december 31, 2019
    		                                
      related party contract liability
    		                    44,854,000            
      other contract liabilities
    		                    28,015,000            
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2020 and december 31, 2019; 0 shares issued and outstanding as of september 30, 2020 and december 31, 2019
    		                                
      contract liabilities
    		                     34,134,000 24,674,000 18,739,000 18,185,000 22,598,000 23,148,000      
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2020 and december 31, 2019; 0 shares issued and outstanding as of june 30, 2020 and december 31, 2019
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2020 and december 31, 2019; 0 shares issued and outstanding as of march 31, 2020 and december 31, 2019
    		                                
      deferred rent, less current portion
    		                           24,532,000 7,103,000 1,029,000 6,051,000  
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2019 and december 31, 2018; 0 shares issued and outstanding as of december 31, 2019 and december 31, 2018
    		                                
      accrued liabilities
    		                        15,467,000 13,793,000 12,114,000 8,520,000 7,393,000 5,537,000 4,425,000  
      other current liabilities
    		                        3,483,000 2,135,000 1,107,000 380,000 138,000 47,000 63,000  
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2019 and december 31, 2018; 0 shares issued and outstanding as of september 30, 2019 and december 31, 2018
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2019 and december 31, 2018; 0 shares issued and outstanding as of june 30, 2019 and december 31, 2018
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2019 and december 31, 2018; 0 shares issued and outstanding as of march 31, 2019 and december 31, 2018
    		                                
      contract liability
    		                           11,427,000 12,658,000 8,715,000 8,434,000  
      deferred rent
    		                           616,000 3,227,000 4,782,000 874,000  
      contract liability, less current portion
    		                           57,350,000 44,452,000 49,590,000 51,519,000  
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2018 and december 31, 2017; 0 shares issued and outstanding as of december 31, 2018 and december 31, 2017
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2018 and december 31, 2017; 0 shares issued and outstanding as of september 30, 2018 and december 31, 2017
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2018 and december 31, 2017; 0 shares issued and outstanding as of june 30, 2018 and december 31, 2017
    		                                
      convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2018 and december 31, 2017; 0 shares issued and outstanding as of march 31, 2018 and december 31, 2017
    		                                
      consolidated balance sheets data:
    		                                
      cash, cash equivalents and marketable securities
    		                               466,976,000 
      working capital
    		                               395,443,000 
      convertible preferred stock
    		                                
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.